A machine sale records a buyer’s decision to install capacity. A dental lab buying another batch of material tells you something about work already running. Stratasys and 3D Systems both grew in the quarter ended 30 September 2026, but their disclosures give different views of those two decisions.

| Q3 2026, USD | Stratasys (SSYS) | 3D Systems (DDD) |
|---|---|---|
| Revenue | $142.6m | $99.3m |
| Reported year-over-year growth | 4.1% | About 9% |
| GAAP gross margin | 43.7% | 35.0% |
| GAAP net loss | $10.2m | $33.5m |
Stratasys sold more systems while consumables softened
Systems revenue reached $35.9 million, up about 12% year over year. Stratasys also reported lower consumables revenue and cited longer sales cycles for larger production orders when it cut full-year revenue guidance to $556–561 million. A system delivered late in a quarter may contribute little material demand in that period. The release gives no fleet-level measure of machine use. Stratasys Q3 release, 12 November.
3D Systems saw demand from healthcare production
Healthcare revenue reached $49.0 million. The company reported growth above 20% in each of two activities, healthcare parts manufacturing and dental materials sales. Industrial revenue reached $50.3 million, up about 4%. Dental material sales are a closer indicator of ongoing print activity than an equipment order, although pricing and customer inventories also affect the number. 3D Systems Q3 release, 4 November.
Two questions for the next report
SSYS. Does consumables revenue recover after the stronger systems quarter? Look for a disclosed figure or explicit management commentary before inferring higher use.
DDD. Do healthcare production and dental materials sustain growth, and does more gross profit reach the operating line? Track the same reported measures each quarter. The companies group revenue differently, so their segment percentages cannot be compared directly. Save the names through the Company Database and follow the dated updates in Alerts.

Leave a Reply